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outpatientsBackground/Purpose: The aim of this study was to examine the correlations between the
severity of alprazolam dependence and socio-demographic characteristics, the characteristics
of alprazolam use, psychiatric comorbidity, and beliefs toward alprazolam use among long-
term alprazolam users in Taiwan.
Methods: A total of 148 long-term alprazolam users participated in this study. The Chinese
version of the Severity of Dependence Scale was used to assess participants’ severity of alpraz-
olam dependence in the preceding month. Their socio-demographic characteristics, family
function characteristics, dosage of prescribed alprazolam, duration of alprazolam use, alcohol
use pattern, pain reliever and cigarette use pattern, severity of depressive symptoms, psychi-
atric diagnosis, and belief toward alprazolam use were investigated.
Results: The results of multiple regression analysis indicated that a longer duration of alpraz-
olam use, severe depressive symptoms, a high level of belief in the necessity of alprazolam
treatment, and a high level of concern about the potential adverse consequences of alprazo-
lam use were significantly associated with more severe alprazolam dependence.
Conclusion: Doctors should closely monitor the severity of alprazolam dependence among
long-term users, especially patients’ levels of depression, beliefs in the necessity of alprazo-
lam treatment, and their concerns over the adverse consequences of continued treatment
with alprazolam.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Alprazolam, a benzodiazepine (BZD) with a short elimina-
tion half-life, high potency, and rapid onset of action,1 is
commonly used for the medical treatment of anxiety dis-
orders such as panic disorder and generalized anxiety dis-
order. Although selective serotonin reuptake inhibitors are
recommended as the first-line pharmaceutical agents for
treating anxiety disorders,2 alprazolam is still one of the
most frequently prescribed drugs in many countries,
including the USA,3 Australia,4 and Taiwan.5 Alprazolam,
with its short elimination half-life, causes a more severe
withdrawal syndrome and has a higher physical dependence
liability than BZDs with longer elimination half-lives.6 In
addition, the high-potency characteristics of alprazolam
also increase the susceptibility of physical dependence
compared with BZDs with low potency.7 Alprazolam has
reinforcing effects, which are demonstrated when rates of
drug self-administration exceed those of vehicle self-
administration.8 It is not recommended to use alprazolam
for long periods of time because of the increased risk of
developing dependence, as with other BZDs.9 The rein-
forcing effects of alprazolam increase the potential of
psychological dependence, which is a serious issue that
should be monitored among patients treated with BZD in
the long term.10 Alprazolam deserves particular attention
because of its reinforcing capabilities, withdrawal syn-
drome, potential for addiction, and potential for negative
consequences of use.11,12
It is well recognized that dependence on BZDs develops
not only with high doses, but also with long-term thera-
peutic doses.6 Identification of the factors characterizing
BZD dependence can serve as the basis of prevention, early
detection, and intervention programs for BZD dependence.
Doctors must often choose among several different drugs
for patients with anxiety. Thus they must know how to
identify individuals who may be at risk of iatrogenicdependence on alprazolam and other anxiolytic drugs.
Early identification of these patients would not only assist
in treatment planning, but could ultimately result in
greater patient satisfaction and better treatment re-
sponses. Previous studies have shown that female sex,13,14
old age,15 being widowed or divorced,13 a high educa-
tional level,13 unemployment,15 long duration of use,13 high
daily dosage of hypnotic drugs,15 severe mood symptoms,15
and alcohol dependence15 are significantly associated with
the use of BZD spectrum anxiolytic and hypnotic drugs.
Patterns of alprazolam use are influenced by age, sex, and
history of alcohol dependence.16 It is especially pertinent
to examine patients’ beliefs regarding the use of alprazo-
lam. According to social cognitive theory,17 expectancies of
positive or negative outcomes have a strong influence on
drug-using behavior. Nonetheless, the relationships be-
tween alprazolam dependence and beliefs toward alpraz-
olam use are largely unclear.
The aim of this study was to examine the associations
between the severity of alprazolam dependence and socio-
demographic characteristics, characteristics of alprazolam
use, psychiatric comorbidity, and beliefs regarding alpraz-
olam use among long-term alprazolam users in Taiwan.
Materials and methods
Participants
Patients aged between 20 years and 50 years from the
psychiatric outpatient clinics of six general hospitals in
Taiwan who had used alprazolam for at least 3 months as an
anxiety treatment were consecutively invited to partici-
pate in this study. Volunteers underwent a screening
interview during the period March 2012 to November 2012.
The period of 3 months of use of this hypnotic drug was
determined based on the fact that hypnotic drugs often
lose their sedative effect after a few months of regular
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geographical regions of Taiwan (North Taiwan, Tao-Chu-
Miao, Central Taiwan, Chia-Nan, Kao-Ping, and East
Taiwan). Patients who used both alprazolam and other
kinds of BZDs as anxiolytic drugs at the same time were
excluded. Those who were unable to complete the study
interviews due to obvious psychotic symptoms or cognitive
deficits were also excluded. A total of 173 alprazolam users
were invited to participate in this study. Of these, 148
(85.5%) agreed to participate and were interviewed by the
research assistants based on the research questionnaire.
There was no difference in sex (c2 Z 0.315, p Z 0.575) or
age (t Z 0.212, p Z 0.833) between those patients who
participated in this study and those who refused to
participate. The protocol was approved by the institutional
review board of each hospital at which the study was
conducted.Measures
Seven research assistants (2 in the hospital of Kao-Ping
Region and 1 in each hospital of the other regions) per-
formed interviews based on research questionnaires to
gather information from the participants. All the research
assistants were either currently nurses or had previously
worked as nurses. This study used the following strategies
to improve the reliability of the ratings among the research
assistants. Firstly, the principal investigator of this study
(C.-F. Y.) discussed and practiced the interviews with the
two research assistants in the hospital of Kao-Ping Region to
ensure they had a comprehensive understanding of the
interview. These two trained research assistants then went
to the other research sites outside the Kao-Ping Region to
train the other research assistants in the interview tech-
nique based on the research questionnaires. Thirdly, the
two main research assistants contacted the other assistants
every month to discuss any problems encountered in the
interviews. Research assistants who had questions about
the interviews could discuss these with the principal
investigator and the two main research assistants to resolve
their doubts.
The five-item Chinese version of the Severity of Depen-
dence Scale (SDS[Ch]) was used to assess participants’
severity of alprazolam dependence in the previous
month.19,20 The total SDS[Ch] scores range from 0 to 15, with
a higher score indicating a greater degree of alprazolam
dependence. The SDS is a valid, brief, self-report ques-
tionnaire for the assessment of BZD dependence in patients
using BZDs.21 The psychometrics of the SDS[Ch] for patients
who use hypnotic drugs have been examined in Taiwan and
the results support the validity of the SDS[Ch] to differen-
tiate BZD-dependent users from those without BZD
dependence.22 The internal consistency (Cronbach a) of the
SDS[Ch] in this study was 0.70.
This study also collected four dimensions of data from
the participants, including socio-demographic characteris-
tics, characteristics of alprazolam use, psychiatric comor-
bidities, and beliefs toward alprazolam use. Participants’
sex, age, educational level, marital status (not single vs.
single), job status (having a fixed job vs. no fixed job), and
perceived family function were investigated. Those whowere unmarried, divorced, separated, or were surviving
spouses were classified as single; those who were married
or lived with a partner were categorized as not single. The
levels of family function perceived by the participants were
determined based on the self-reported Chinese version of
the five-item Family APGAR Index.23,24 The five-point
response scale reflects frequency, which ranges from
never to always. High total scores indicate satisfactory
perceived family function. A previous study in Taiwan has
found that the Chinese version of the Family APGAR Index
can differentiate individuals who have family problems
from those who have no family problems.23 The internal
consistency (Cronbach a) of the Family APGAR Index in this
study was 0.88. The research assistants also examined the
total dosage of prescribed alprazolam and total duration of
taking alprazolam among the participants based on their
medical records.
The psychiatric comorbidities considered included
habitual substance use, the severity of depressive symp-
toms, and psychiatric diagnoses. Three questions from the
Chinese version of the Drug Use Disorders Identification
Test were used to survey the use of alcohol, pain-relieving
drugs, and cigarettes in the previous month.25,26 Partici-
pants who used alcohol, pain-relieving drugs, or cigarettes
four times or more in each week of the previous month
were classified as habitual alcohol, pain-relieving drug, or
cigarette users. The severity of depressive symptoms in the
past week was determined using the 20-item Mandarin
Chinese version of the Center for Epidemiological Studies-
Depression Scale (CES-D).27,28 The CES-D is a self-
administered four-point evaluation scale assessing the fre-
quency of depressive symptoms in the past week, with
scores ranging from 0 (none or very few) to 3 (always). High
CES-D scores indicate severe depressive symptoms. A pre-
vious study has found that the Mandarin Chinese version of
the CES-D has good reliability and has found that depressive
symptoms measured by the CES-D were significantly asso-
ciated with the levels of daily life activities, self-reported
health, and life satisfaction.29 The internal consistency
(Cronbach a) of the CES-D in this study was 0.86. The pri-
mary psychiatric diagnosis for each participant [based on
the International Classification of Diseases, 9th Revision,
Clinical Modification, (ICD-9-CM)] was determined from the
patients’ medical records. For those who had several psy-
chiatric diagnoses, the psychiatrist who referred the pa-
tients to this study made the decision about which diagnosis
was the primary one based on their clinical judgment and
the patients’ clinical conditions. Unipolar depression-
related disorders (296.2, 296.3, 298.0, and 298.1) and
neurotic disorder and other non-psychotic mental disorders
(300e316) were merged into the category of “anxiety or
depressive disorders”. Participants who had diagnoses
other than those just described were classified as having no
anxiety or depressive disorders.
We used the Beliefs toward Medicines Questionnaire
(BMQ) to evaluate the beliefs of participants toward
receiving alprazolam treatment for their anxiety prob-
lems.30 The 10-item BMQ consists of two five-item subscales
and a higher total score on the subscales indicates that the
participants had a higher belief in the need for prescribed
alprazolam to improve their anxiety and a higher level of
concern about the potential adverse consequences of
Table 1 Severity of alprazolam dependence, socio-
demographic and alprazolam use characteristics, psychiatric
comorbidity, and belief regarding treatment with alprazolam
(nZ 148).
Severity of alprazolam dependence 5.4  3.3
Socio-demographic characteristics
Sex
0: Female 80 (54.1)
1: Male 68 (45.9)
Age (y) 42.2  8.8
Marital status
0: Not single 60 (40.5)
1: Single 88 (59.5)
Educational level 12.7  3.3
Fixed job
0: No 80 (54.1)
1: Yes 68 (45.9)
Family function on the APGAR scale 14.1  4.3
Characteristics of alprazolam use
Dosage of alprazolam (mg/d) 1.0  1.2
Duration of taking alprazolam (mo) 51.2  56.0
Psychiatric comorbidity
Regular alcohol drinking
0: No 141 (95.3)
1: Yes 7 (4.7)
Regular use of pain-relieving drugs
0: No 128 (86.5)
1: Yes 20 (13.5)
Regular smoker
0: No 108 (73.0)
1: Yes 40 (27.0)
Severity of depressive
symptoms on the CES-D scale
23.8  15.3
Diagnosis of anxiety or
depressive disorders
0: No 96 (64.9)
1: Yes 52 (35.1)
Level of belief toward
alprazolam use on the BMQ
Necessity 17.2  5.2
Concern 13.7  4.4
Data are presented as n (%) or mean  SD.
APGAR Z Family APGAR Index; BMQ Z Beliefs about Medicines
Questionnaire; CES-D Z Center for Epidemiological Studies-
Depression Scale.
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that both the need and concern subscales of the BMQ were
significantly associated with medical adherence.30 The
internal consistencies (Cronbach a) of the need and
concern subscales of the BMQ in this study were 0.71 and
0.74, respectively.Statistical analysis
Data analysis was performed using SPSS 15.0 statistical
software (SPSS Inc., Chicago, IL, USA). The levels of
alprazolam dependence in the previous month from the
SDS[Ch] were calculated as means and standard deviations.We used four multiple regression analysis models to
examine the factors associated with the severity of
alprazolam dependence. Socio-demographic characteristics
were first selected into the first multiple regression analysis
model, followed by the characteristics of alprazolam use,
psychiatric comorbidity, and belief toward alprazolam use
in a step by step manner. In every regression model the
variables were selected into the regression model by the
“enter” method. A p value < 0.05 was used to indicate
significance for all statistical tests.
Results
Table 1 shows the severity of alprazolam dependence,
socio-demographic characteristics, characteristics of al-
prazolam use, psychiatric comorbidities, and beliefs toward
alprazolam use. Table 2 gives the results of multiple
regression analysis examining the factors associated with
the severity of alprazolam dependence. The results of
Model I did not identify any significant association between
alprazolam dependence and socio-demographic character-
istics. The characteristics of alprazolam use were input into
Model II. A long duration of alprazolam use was significantly
associated with severe alprazolam dependence (Model II)
after controlling for the effects of socio-demographic
characteristics. Psychiatric comorbidity was selected into
Model III. Severe depressive symptoms were significantly
associated with severe alprazolam dependence (Model III)
after controlling for socio-demographic characteristics and
alprazolam use. Belief regarding alprazolam use was
selected into Model IV. A strong belief in the necessity of
alprazolam treatment and a high level of concern about the
potential adverse consequences of alprazolam use were
significantly associated with severe alprazolam dependence
(Model IV) after controlling for socio-demographic charac-
teristics, characteristics of alprazolam use, and psychiatric
comorbidity. Model IV accounted for most of the variance
(p < 0.001; adjusted R2 Z 0.320).
Discussion
This study explored the factors associated with the severity
of alprazolam dependence. We found that a greater belief
in the necessity of alprazolam treatment was the most
influential factor related to alprazolam dependence. Based
on the Health Belief Model,31 patients’ assessments of the
positive consequences of taking alprazolam may make them
continue to use alprazolam, which further increases the
vulnerability of an individual to develop alprazolam
dependence. Research also showed that a greater fre-
quency of alprazolam use was predicted by less extrover-
sion, lower internal health locus of control, a strong belief
in powerful others, and greater avoidance behavior.32
Furthermore, the frequency with which the participants
with a low internal locus of control consumed capsules
(alprazolam or placebo) was stable across the 6 week study
period, and the stability of these patterns persisted
regardless of what kind of drug the capsules contained.32
Based on the results of our study and the study of Oswald
et al,32 we hypothesized that a low internal locus of control
might affect users’ beliefs toward the necessity of
Table 2 Factors associated with alprazolam dependence: multivariate regression analysis.
Model I Model II Model III Model IV
b t p b t p b t p b t p
Sex 0.115 1.362 0.175 0.099 1.183 0.239 0.108 1.233 0.220 0.118 1.471 0.144
Age 0.045 0.466 0.642 0.017 0.169 0.866 0.010 0.106 0.916 0.034 0.377 0.707
Marital status 0.025 0.267 0.790 0.067 0.704 0.483 0.069 0.745 0.457 0.062 0.730 0.467
Educational level 0.121 1.328 0.186 0.110 1.220 0.224 0.060 0.650 0.517 0.020 0.238 0.812
Fixed job 0.055 0.627 0.531 0.044 0.504 0.615 0.052 0.603 0.548 0.002 0.019 0.985
Perceived family function 0.123 1.412 0.160 0.135 1.570 0.119 0.031 0.348 0.729 0.002 0.028 0.977
Dosage of alprazolam 0.020 0.236 0.814 0.007 0.083 0.934 0.002 0.026 0.979
Duration of treatment with
alprazolam
0.223 2.566 0.011 0.204 2.360 0.020 0.115 1.427 0.156
Regular drinking of alcohol 0.053 0.634 0.527 0.005 0.069 0.945
Regular use of pain-relieving
drugs
0.044 0.526 0.599 0.007 0.093 0.926
Regular smoker 0.079 0.919 0.360 0.044 0.563 0.574
Depressive symptoms 0.266 2.900 0.004 0.091 1.007 0.316
Have anxiety or depressive
disorders
0.019 0.224 0.823 0.080 1.025 0.307
Belief toward alprazolam
use: necessity
0.343 4.072 < 0.001
Belief toward alprazolam
use: concern
0.232 2.880 0.005
F 1.102 1.796 2.078 4.150
p 0.364 0.083 0.019 <0.001
Adjusted R2 0.045 0.094 0.168 0.320
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1102 T.-T. Chen et al.alprazolam use and then increase the risk of alprazolam
dependence. Further research is needed to explore this
hypothesis. In additional, we also found that a higher level
of concern about the potential adverse consequences of
alprazolam was associated with a higher level of alprazolam
dependence. Given that the side effects of drug use are one
of the leading causes of poor adherence to prescribed
drugs,33 it is reasonable to hypothesize that those who have
a higher level of concern about the potential adverse con-
sequences of alprazolam might also have a lower level of
alprazolam dependence. However, the results of this study
did not support this hypothesis. Nonetheless, because of
the study’s cross-sectional research design, the causal
relationship between alprazolam use and concern about its
potential adverse consequences could not be determined.
It is possible that concern about the potential adverse
consequences of alprazolam develops after the long-term
use of alprazolam or dependence on alprazolam. In addi-
tion, patients using alprazolam might have an ambivalent
attitude toward alprazolam use. They might believe that
persistent use of alprazolam is essential to the treatment of
their mental illnesses and they may also worry about the
potential adverse consequences of alprazolam. They might
struggle with the ambivalence of the belief regarding al-
prazolam and therefore not make the decision to refrain
from alprazolam use. Education is the key to helping pa-
tients using alprazolam to benefit from the drug while
preventing its adverse effects.
In addition to the beliefs regarding alprazolam, the
findings also demonstrated that severe depressive symp-
toms were significantly associated with severe alprazolam
dependence. Depressive symptoms were often accompa-
nied by symptoms of anxiety and insomnia. Although anti-
depressants are recommended for the treatment of
depression, BZDs are often initially prescribed in combi-
nation with antidepressants to alleviate depressive symp-
toms. Because BZDs such as alprazolam have sedative and
euphoric effects and also act rapidly, they are often used in
clinical practice for the treatment of depression. For
example, alprazolam appeared to reduce depressive
symptoms secondary to anxiety disorders more effectively
than a placebo and as effectively as tricyclic antidepres-
sants.34,35 Nonetheless, the studies included in these re-
views were heterogeneous, of poor quality, and only
addressed short-term effects, which limits confidence in
the findings.34 The disadvantages of BZDs include masking
or aggravating the symptoms of depression and increasing
the risks of suicide, especially with long-term use.36,37 In
Taiwan, Lai et al38 found that a high percentage of the BZDs
prescribed were used alone for the treatment of serious
depression and that the BZD prescribing guidelines did not
reduce this rate. Alprazolam was not included in the study
by Lai et al38 and this observation is a cause for substantial
concern. It is also noteworthy that depressive symptoms
may reduce the motivation of patients treated with al-
prazolam to abstain from its use.
The study results indicated that a long duration of
treatment with alprazolam was significantly associated
with severe alprazolam dependence after controlling for
the effects of socio-demographic characteristics. Although
current guidelines recommend that alprazolam should be
used for only a short period of time, problems of alprazolamdependence arose in many patients.39,40 According to the
Pharmaceutical Benefits Scheme of Australia,41 in spite of a
significant overall reduction in BZD prescribing, alprazolam
sales have risen by 28%. The Medical Practitioners Board in
Victoria, Australia issued a warning in 2009 that alprazolam
was subject to non-medical use and caused a dispropor-
tionally higher level of significant harm than other BZDs.41
Romach et al16 found that, although most patients
treated with long-term alprazolam complied with the as-
prescribed and as-needed use, 21% increased their dose,
disregarding their prescriptions. A community-based study
in Canada about long-term treatment with alprazolam
found that some patients persistently used alprazolam, but
that this did not represent behavioral abuse or depen-
dence.42 The majority of patients undergoing long-term
treatment with alprazolam considered that they benefited
from alprazolam; however, they had not discussed discon-
tinuation with their doctors, but tried to taper the drug by
themselves.41 The results of this and previous studies
remind doctors that it is necessary to discuss the disad-
vantages of long-term treatment with alprazolam and the
need to taper its dosage as the clinical problem improves.
The study results need to be interpreted in the light of
several limitations. First, although we excluded those par-
ticipants who used anxiolytic drugs other than alprazolam,
we did not examine whether the participants used other
BZDs as hypnotic drugs. In addition, the information was
provided by the participants themselves and it could not be
ruled out that the participants may take alprazolam or other
BZDs as anxiolytic drugs from other sources. Second, we did
not review the history of former anxiolytic drug use by the
participants in this cross-sectional study. Patients could
have experienced adverse consequences with other anxio-
lytic drugs and then projected those consequences onto
their current use of alprazolam. Previous experience with
anxiolytic drugs could have influenced the participants’
beliefs toward their current alprazolam regimen and usage
patterns. Third, the measurements were restricted to self-
reporting by the participants, although those who were
unable to complete the study interviews due to obvious
psychotic symptoms or cognitive deficits were excluded.
Report bias should be taken into consideration when inter-
preting the results of this study. In addition, participants’
psychiatric diagnoses were reviewed from their medical
records, not from structural interviews. These confounding
factors restrict the interpretation of our results. Finally, the
cross-sectional research design limits the establishment of
causal relationships between the severity of alprazolam
dependence and significantly associated factors. During the
literature review, we found little data discussing the
severity of alprazolam dependence and its associated cau-
ses. A future study with a larger sample size is needed to
evaluate and verify the features associated with the severity
of alprazolam dependence identified in this study.
In conclusion, these findings showed that the level of
belief toward alprazolam use, the severity of depressive
symptoms, and the duration of treatment with alprazolam
use significantly associated with the severity of alprazolam
dependence. Doctors should monitor the risk of alprazolam
dependence among patients treated with alprazolam in the
long term, especially those with severe depression, a strong
belief in the necessity of alprazolam treatment, and
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continued treatment with alprazolam.Acknowledgments
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